There are many pharma companies with the ability to make a fast-track FDA approved vaccine for H7N9. There is a lot of competition for Inovio in this field.
As H7N9 has indicated, new influenza subtypes appear more often and they are getting more dangerous.
A vaccine for each new mutation needs some months, but even if it achieved in this short time, the virus can be mutated until then!
What differs INOVIO from other companies, is the SynCon technology. SynCon universal influenza vaccines are focused to be capable of broad protection against existing and newly emergent unmatched strains.
And very recently, INOVIO has proved, in a early stage though, at phase I, that they have achieved the same protective levels with the other vaccines.
INOVIO is the company which has already focused and can resolve the major problem of influenza, the frequent mutations.
This is not something the market can understand promptly, but beyond a few longs and a few shorters, there is a real market out there and INOVIO gets more known with Dr. Kim's interviews about influenza, with the ViE awards, and the publicity of SynCon influenza vaccines worldwide (pharmabiz India, Abu Dhabi topnews etc). Time will tell.
China bird flu may be two mutations from a pandemic
17:21 10 April 2013 by Debora MacKenzie
In China, nine people have died and more than 20 are seriously ill in the latest outbreak of bird flu, H7N9. And there are fears that the death toll could rise much higher because the virus already has three of the five mutations that we know could allow another bird flu, H5N1, to spread between mammals.
No one knows for sure if the five mutations discovered last year by Ron Fouchier and colleagues at Erasmus Medical Center in Rotterdam, the Netherlands, will do the same thing in H7N9. But we do know that some of the mutations helped viruses from three other flu families go pandemic. For the moment, Chinese authorities tracing contacts of known cases say there is no evidence yet that the infection has spread between humans.
Most recent pandemic viruses have been hybrids of bird and mammalian flu, and therefore relatively mild because mammalian flu tends to be less severe in people than bird flu. Pure bird flu viruses, like H5N1 and H7N9, are potentially more dangerous. The most lethal pandemic we know of, which spread across the world in 1918, was a pure bird flu that acquired mutations that allowed it to spread in humans. Virologists fear H7N9 could be doing that.
BTD status is available after a successful phase I if the drug is for an unmet need. It's like the criteria was written with INO in mind. As Dr. Kim said, the entire vaccination industry and concept is still back in the '50's. It won't be long now. INO is a fantastic opportunity...
Sentiment: Strong Buy
Not to get too excited Martha, but you're right; INO is the only one with a platform to offer broad protection, and being one step ahead of the mutations. Breakthrough Drug Designation after this very successful Phase I, or Accelerated Approval would really move the pps.
Sentiment: Strong Buy
In the United States, scientists at the Centers for Disease Control and Prevention have received samples of the virus from China and have shared them with five other laboratories to study the virus and work on a vaccine. see NYT article 4/25
Yes, I have read it, thanks. The problem is that by making a vaccine about this form of H7N9 only, we continue the endless race to achieve protection from every mutation separately. Until now, only INOVIO focus to a broad protection vaccine and have some positive results.